Human RCTPubMed ID: 39125847·2025

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Younossi ZM, Guyonnet S, Yilmaz Y, et al.

Journal of Hepatology, 2025 · n = 385

Key finding

Retatrutide 15mg achieved NASH resolution in 43% vs 9% placebo; F1-F3 fibrosis improved by 18% vs 3% placebo.

Summary

Phase 3 trial evaluating retatrutide (10, 15mg) versus placebo in NASH patients with fibrosis, measuring liver histology and fibrosis regression over 52 weeks.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT

TRIUMPH 2: Retatrutide in Type 2 Diabetes and Obesity

Diabetes Care · 2024 · Human RCT